KR101900016B1 - 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트 - Google Patents

폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트 Download PDF

Info

Publication number
KR101900016B1
KR101900016B1 KR1020117023448A KR20117023448A KR101900016B1 KR 101900016 B1 KR101900016 B1 KR 101900016B1 KR 1020117023448 A KR1020117023448 A KR 1020117023448A KR 20117023448 A KR20117023448 A KR 20117023448A KR 101900016 B1 KR101900016 B1 KR 101900016B1
Authority
KR
South Korea
Prior art keywords
biomarkers
leu
ser
expression
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117023448A
Other languages
English (en)
Korean (ko)
Other versions
KR20120010229A (ko
Inventor
로버트 티 스트립퍼
엘즈비에타 이즈비카
성 에이치 백
Original Assignee
캔서 프리벤션 앤 큐어, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/403,369 external-priority patent/US8541183B2/en
Application filed by 캔서 프리벤션 앤 큐어, 리미티드 filed Critical 캔서 프리벤션 앤 큐어, 리미티드
Publication of KR20120010229A publication Critical patent/KR20120010229A/ko
Application granted granted Critical
Publication of KR101900016B1 publication Critical patent/KR101900016B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117023448A 2009-03-12 2010-03-12 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트 Active KR101900016B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/403,369 2009-03-12
US12/403,369 US8541183B2 (en) 2007-09-11 2009-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US23719809P 2009-08-26 2009-08-26
US61/237,198 2009-08-26
PCT/US2010/027243 WO2010105235A2 (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026414A Division KR102061441B1 (ko) 2009-03-12 2010-03-12 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트

Publications (2)

Publication Number Publication Date
KR20120010229A KR20120010229A (ko) 2012-02-02
KR101900016B1 true KR101900016B1 (ko) 2018-09-20

Family

ID=42729154

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117023448A Active KR101900016B1 (ko) 2009-03-12 2010-03-12 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트
KR1020187026414A Active KR102061441B1 (ko) 2009-03-12 2010-03-12 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187026414A Active KR102061441B1 (ko) 2009-03-12 2010-03-12 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트

Country Status (10)

Country Link
US (1) US11474104B2 (enExample)
EP (4) EP3444359A1 (enExample)
JP (7) JP2012520469A (enExample)
KR (2) KR101900016B1 (enExample)
CN (4) CN108181457B (enExample)
AU (3) AU2010223911A1 (enExample)
CA (2) CA3024643C (enExample)
ES (1) ES2703714T3 (enExample)
PL (1) PL3257953T3 (enExample)
WO (1) WO2010105235A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
AU2012249288C1 (en) * 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
WO2017044715A1 (en) * 2015-09-09 2017-03-16 Somalogic, Inc. Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles
KR102087373B1 (ko) * 2015-09-11 2020-03-10 주식회사 압타머사이언스 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112501140B (zh) * 2020-12-16 2022-03-18 熊猫乳品集团股份有限公司 一种生物活性多肽yfgsgfaapffivrhqllkk及其制备方法和应用
TWI796010B (zh) * 2021-11-23 2023-03-11 國立高雄大學 基質金屬蛋白酶-1胜肽拓印導電聚合物及其用途
CN117907508A (zh) * 2023-12-19 2024-04-19 查理高特(青岛)健康科技有限公司 基于代谢组学的高尿酸血症及尿酸性肾病的风险预测系统

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004600A2 (en) 2000-07-12 2002-01-17 Smithkline Beecham Corporation Novel compounds
US20030104499A1 (en) 2001-03-12 2003-06-05 Monogen, Inc. Cell-based detection and differentiation of lung cancer
WO2004073623A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
US20060084126A1 (en) 2004-10-20 2006-04-20 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
WO2006118522A1 (en) * 2005-04-29 2006-11-09 Astrazeneca Ab Peptides as biomarkers of copd
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
WO2008063413A2 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
US20070092917A1 (en) 1998-05-01 2007-04-26 Isabelle Guyon Biomarkers for screening, predicting, and monitoring prostate disease
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
EP1157041B1 (en) 1999-03-01 2005-06-01 Genentech, Inc. Antibodies for cancer therapy and diagnosis
FI990888A0 (fi) * 1999-04-20 1999-04-20 Medix Biochemica Ab Oy Menetelmä ja testikittejä respiratorisen alueen tulehduksen läsnäolon ja vaikeusasteen arvioimiseksi
CA2371385A1 (en) * 1999-04-26 2000-11-02 Surromed, Inc. Phenotype and biological marker identification system
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
EP1801240A1 (en) 2001-06-05 2007-06-27 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
US20030134339A1 (en) 2002-01-14 2003-07-17 Thomas Brown Proteomics based method for toxicology testing
JP2005522228A (ja) 2002-04-11 2005-07-28 オックスフォード グライコサイエンシス （ユーケイ） リミテッド 癌に関与するタンパク質
US20060088894A1 (en) 2002-05-10 2006-04-27 Eastern Virginia Medical School Prostate cancer biomarkers
AU2003240495A1 (en) * 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
AU2004253846A1 (en) * 2003-03-04 2005-01-13 Wyeth Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases
CN1795187A (zh) * 2003-03-27 2006-06-28 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
JP2005044330A (ja) 2003-07-24 2005-02-17 Univ Of California San Diego 弱仮説生成装置及び方法、学習装置及び方法、検出装置及び方法、表情学習装置及び方法、表情認識装置及び方法、並びにロボット装置
JP4938451B2 (ja) 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 非小細胞肺癌の診断のための方法
AU2005231101A1 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20090297563A1 (en) * 2004-10-27 2009-12-03 Anders Borglum Diagnosis And Treatment of Immune-Related Diseases
BRPI0518734A2 (pt) 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
CN1300580C (zh) 2004-12-31 2007-02-14 中国人民解放军第306医院 检测肝癌血清特征蛋白的质谱模型及其制备方法和应用
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JPWO2007026773A1 (ja) 2005-08-31 2009-03-12 学校法人 久留米大学 医用診断処理装置
EP2269724A1 (de) 2005-10-29 2011-01-05 Bayer Technology Services GmbH Verfahren zur Bestimmung eines oder mehrerer Analyten in komplex zusammengesetzten Proben biologischen Ursprungs und dessen Verwendung
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
KR100760518B1 (ko) 2006-07-18 2007-09-20 삼성정밀공업 주식회사 가구용 도어의 닫힘 충격 완충 장치
US7840505B2 (en) 2006-11-02 2010-11-23 George Mason Intellectual Properties, Inc. Classification tool
WO2008077022A2 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Himf and btk in pulmonary, cardiac, and inflammation disorders
JP5085927B2 (ja) 2006-12-21 2012-11-28 ウィンテックポリマー株式会社 難燃性樹脂組成物
EP2139919A2 (en) * 2007-02-28 2010-01-06 Novimmune Sa Human anti-ip-10 antibodies and uses thereof
AU2008236634A1 (en) 2007-04-05 2008-10-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP2515116A1 (en) 2007-05-18 2012-10-24 Duke University Serum biomarkers for the early detection of lung cancer
EP2156187A4 (en) 2007-06-15 2010-07-21 Biosite Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND / OR PROGNOSIS OF OVARY CANCER AND LUNG CANCER
US7888051B2 (en) * 2007-09-11 2011-02-15 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US20090069189A1 (en) 2007-09-11 2009-03-12 Cancer Prevention And Cure, Ltd. Method of identifying proteins in human serum indicative of pathologies of human lung tissues
JP5159242B2 (ja) 2007-10-18 2013-03-06 キヤノン株式会社 診断支援装置、診断支援装置の制御方法、およびそのプログラム
WO2009074276A2 (en) 2007-12-10 2009-06-18 Roche Diagnostics Gmbh Marker panel for colorectal cancer
CA2878025C (en) 2008-01-18 2018-12-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
EP2329260A4 (en) 2008-03-04 2011-08-03 Ridge Diagnostics Inc DIAGNOSIS AND MONITORING OF DEPRESSIVE DISORDERS BASED ON A PLURALITY OF BIOMARKER PANELS
CN101587125B (zh) 2008-05-21 2013-07-24 林标扬 高表达癌症标记物和低表达组织器官标记物组合试剂盒
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA3011730C (en) 2008-09-09 2022-05-17 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN101988059B (zh) 2009-07-30 2014-04-02 江苏命码生物科技有限公司 胃癌检测标记物及其检测试剂盒和生物芯片
CN103582815A (zh) 2011-02-24 2014-02-12 佛米利昂公司 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
AU2012249288C1 (en) 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015066564A1 (en) 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015138769A1 (en) 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004600A2 (en) 2000-07-12 2002-01-17 Smithkline Beecham Corporation Novel compounds
US20030104499A1 (en) 2001-03-12 2003-06-05 Monogen, Inc. Cell-based detection and differentiation of lung cancer
WO2004073623A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
US20050158401A1 (en) 2003-02-14 2005-07-21 Morris Claudia R. Treatment and diagnosis of conditions associated with elevated arginase activity
JP2006518387A (ja) 2003-02-14 2006-08-10 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
US20060084126A1 (en) 2004-10-20 2006-04-20 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
WO2006118522A1 (en) * 2005-04-29 2006-11-09 Astrazeneca Ab Peptides as biomarkers of copd
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
WO2008063413A2 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAI SongWei et al, Science in China Series C: Life Sciences (2007), vol. 50, no. 3, pp. 305-311.
Iizasa T et al, Clinical Cancer Research (1999), vol. 5, no. 1, pp. 149-153.
Jill M Siegfried et al, The Annals of Thoracic Surgery (1998), vol. 66, pp. 1915-1918.
K Izuhara et al, The Annals of Thoracic Surgery (2006), vol. 13, pp. 2291-2298.
Ma et al, Biochemical and Biophysical Research Communication (2008), vol. 371, no. 3, pp. 425-430.
Tetsuya Okano et al, Proteomics (2006), vol. 6, pp. 3938-3948.

Also Published As

Publication number Publication date
KR102061441B1 (ko) 2019-12-31
KR20120010229A (ko) 2012-02-02
JP6250600B2 (ja) 2017-12-20
AU2016228188A1 (en) 2016-09-29
JP2025114736A (ja) 2025-08-05
EP2406401A4 (en) 2013-01-09
US11474104B2 (en) 2022-10-18
JP2018072348A (ja) 2018-05-10
CA3024643A1 (en) 2010-09-16
JP2024024128A (ja) 2024-02-21
EP3257953A1 (en) 2017-12-20
CN104535765A (zh) 2015-04-22
CN113189342B (zh) 2024-12-03
EP2857522A3 (en) 2015-10-14
AU2018202110A1 (en) 2018-04-19
JP2012520469A (ja) 2012-09-06
JP2016006426A (ja) 2016-01-14
EP3444359A1 (en) 2019-02-20
CA3024643C (en) 2021-08-03
KR20180104190A (ko) 2018-09-19
AU2010223911A1 (en) 2011-10-06
CN102405296A (zh) 2012-04-04
PL3257953T3 (pl) 2019-05-31
CN113189342A (zh) 2021-07-30
ES2703714T3 (es) 2019-03-12
EP2857522A2 (en) 2015-04-08
CA2755301A1 (en) 2010-09-16
AU2018202110B2 (en) 2020-09-03
EP2406401A2 (en) 2012-01-18
JP2022000650A (ja) 2022-01-04
JP6774925B2 (ja) 2020-10-28
WO2010105235A2 (en) 2010-09-16
AU2016228188B2 (en) 2018-01-04
EP3257953B1 (en) 2018-09-26
CA2755301C (en) 2019-01-08
CN108181457A (zh) 2018-06-19
WO2010105235A3 (en) 2011-02-24
JP2019158890A (ja) 2019-09-19
CN108181457B (zh) 2021-03-30
US20180356423A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
KR101900016B1 (ko) 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트
US9933429B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
EP2781913B1 (en) Method for aiding in the diagnosis and therapy of asthma and lung cancer
HK40058647A (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
HK1202619B (en) Method for aiding in the diagnosis and therapy of asthma and lung cancer
AU2016244252A1 (en) Identification of proteins in human serum indicative of pathologies of human lung tissues

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8